Highlights:

• Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy.
• Concurrence with Alterity's plan to target early stage MSA patients.
• Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA.
• Ag...